Patients with relapsed/refractory mantle cell lymphoma respond to CAR T-cell therapy
ORLANDO, Fla. — In a video interview at ASH Annual Meeting and Exposition, Michael L. Wang, MD, professor of lymphoma/myeloma at The Texas University MD Anderson Cancer Center, discussed exciting results from a CAR T-cell therapy study in relapsed/refractory mantle cell lymphoma.Wang reported that the response rate was over 80% and complete response rate was 53% in 28 patents with R/R